Patent granted for Europe

EPO (December 18, 2013)

Swiss Medendi’s patent, has been granted by the the European Patent Office (EPO). The patent covers the core technology of Swiss Medendi’s novel infusion device. The innovation was confirmed to fulfill all three patent criteria: Innovative, inventive, and commercially applicable.

About Swiss Medendi

Swiss Medendi SA is a Switzerland based start-up company offering a proprietary, cost-efficient and easy-to-use intravenous (IV) infusion device, the HC100, for safe administration of chemotherapeutics and other vesicant and irritant drugs – protecting patients’ veins and vessels from vesicant damages, and preventing patients from injuries and complications associated today with ports and catheters. Employing the HC100 will help hospitals to manage costs and enable doctors to focus more on their patients’ needs. For more information on Swiss Medendi, please visit


December 18, 2013